Display options
Cite
Singh A, Gupta A, Chowdhary M, et al. Integrated analysis of miRNA-mRNA networks reveals a strong anti-skin cancer signature in vitiligo epidermis. Exp Dermatol. 2021;30(9):1309-1319doi: 10.1111/exd.14317.
Singh, A., Gupta, A., Chowdhary, M., & Brahmbhatt, H. D. (2021). Integrated analysis of miRNA-mRNA networks reveals a strong anti-skin cancer signature in vitiligo epidermis. Experimental dermatology, 30(9), 1309-1319. https://doi.org/10.1111/exd.14317
Singh, Archana, et al. "Integrated analysis of miRNA-mRNA networks reveals a strong anti-skin cancer signature in vitiligo epidermis." Experimental dermatology vol. 30,9 (2021): 1309-1319. doi: https://doi.org/10.1111/exd.14317
Singh A, Gupta A, Chowdhary M, Brahmbhatt HD. Integrated analysis of miRNA-mRNA networks reveals a strong anti-skin cancer signature in vitiligo epidermis. Exp Dermatol. 2021 Sep;30(9):1309-1319. doi: 10.1111/exd.14317. Epub 2021 Mar 22. PMID: 33682215.
Copy Download .nbib Format: NLM
Share it on

Exp Dermatol. 2021 Sep;30(9):1309-1319. doi: 10.1111/exd.14317. Epub 2021 Mar 22.

Integrated analysis of miRNA-mRNA networks reveals a strong anti-skin cancer signature in vitiligo epidermis.

Experimental dermatology

Archana Singh, Aayush Gupta, Manish Chowdhary, Hemang D Brahmbhatt

Affiliations

  1. CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  2. Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  3. Dr. D. Y. Patil Medical College, Pune, Maharashtra, India.

PMID: 33682215 DOI: 10.1111/exd.14317

Abstract

Expression of microRNAs (miRNAs) is often dysregulated in several cancers, including non-melanoma skin cancer (NMSC). Individuals with vitiligo possess a deregulated miRnome along with a lower risk of developing NMSCs. We used data sets from our previously published studies on vitiligo epidermis to construct functional miRNA-mRNA networks to understand the molecular basis underlying the lower incidence of NMSC observed in individuals with vitiligo. miRTarBase database was used to fetch the experimentally validated targets of differentially expressed miRNAs and two protein-protein interaction (PPI) networks were constructed for the miRNA-mRNA interactions (230 downregulated targets of 5 upregulated miRNAs and 47 upregulated mRNAs targeted by 12 downregulated miRNAs). Pathway enrichment analysis identified RNA biogenesis and transport as well as cell adhesion to be perturbed in vitiligo. Further, oncogenic transcription factors (OTFs) that were upregulated in publicly available squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) microarray data were compared with that of vitiligo to decode skin cancer-specific molecular signatures. We identified three significantly upregulated miRNAs, miR-31-5p, miR-31-3p and miR-194-3p in lesional epidermis that could negatively regulate seven oncogenic transcription factors, FOXC1, AR, SP1, YY1, GLI2, TP53 and RARA, known to be over-expressed in SCC or BCC. Taken together, our study identified a perturbed miRNA-regulated transcriptome, which potentially confers protection to vitiligo skin from an increased incidence of NMSC.

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Keywords: epidermis; miRNA-mRNA networks; microRNAs; non-melanoma skin cancers; vitiligo

References

  1. Ezzedine K, Eleftheriadou V, Whitton M, et al. Vitiligo. Lancet. 2015;386(9988):74-84. - PubMed
  2. Jung S-E, Kang HY, Lee E-S, et al. Changes of epidermal thickness in vitiligo. Am J Dermatopathol. 2015;37(4):289-292. - PubMed
  3. Singh A, Gotherwal V, Junni P, et al. Mapping architectural and transcriptional alterations in non-lesional and lesional epidermis in vitiligo. Sci Rep. 2017;7(1):9860. - PubMed
  4. Schallreuter KU, Tobin DJ, Panske A. Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed caucasian patients with vitiligo. Dermatology. 2002;204(3):194-201. - PubMed
  5. Teulings HE, Overkamp M, Ceylan E, et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br J Dermatol. 2013;168(1):162-171. - PubMed
  6. Cannell IG, Kong YW, Bushell M. How do microRNAs regulate gene expression? Biochem Soc Trans. 2008;36(Pt 6):1224-1231. - PubMed
  7. Wahid F, Shehzad A, Khan T, et al. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010;1803(11):1231-1243. - PubMed
  8. Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012;149(3):515-524. - PubMed
  9. Koshizuka K, Hanazawa T, Fukumoto I, et al. The microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell carcinoma. J Hum Genet. 2017;62(1):3-13. - PubMed
  10. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-269. - PubMed
  11. Srivastava SK, Bhardwaj A, Singh S, et al. MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis. 2011;32(12):1832-1839. - PubMed
  12. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med. 2009;60:167-179. - PubMed
  13. Mansuri MS, Singh M, Dwivedi M, Laddha NC, Marfatia YS, Begum R. MicroRNA profiling reveals differentially expressed microRNA signatures from the skin of patients with nonsegmental vitiligo. Br J Dermatol. 2014;171(5):1263-1267. - PubMed
  14. Brahmbhatt HD, Gupta R, Gupta A, et al. The long noncoding RNA MALAT1 suppresses miR-211 to confer protection from ultraviolet-mediated DNA damage in vitiligo epidermis by upregulating sirtuin 1. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19666 - PubMed
  15. Yu R, Broady R, Huang Y, et al. Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin. PLoS One. 2012;7(12).e51040 - PubMed
  16. Xu P, Wu Q, Yu J, et al. A systematic way to infer the regulation relations of miRNAs on target genes and critical miRNAs in cancers. Front Genet. 2020;11:278. - PubMed
  17. Hsu SD, Lin FM, Wu WY, et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011;39(Database issue):D163-D169. - PubMed
  18. Zhou G, Soufan O, Ewald J, Hancock RE, Basu N, Xia J. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 2019;47(W1):W234-W241. - PubMed
  19. Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447-D452. - PubMed
  20. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11. - PubMed
  21. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504. - PubMed
  22. Atchison ML, Basu A, Zaprazna K, et al. Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects. Crit Rev Oncog. 2011;16(3-4):143-161. - PubMed
  23. Zhang JP, Zhang H, Wang HB, et al. Down-regulation of Sp1 suppresses cell proliferation, clonogenicity and the expressions of stem cell markers in nasopharyngeal carcinoma. J Transl Med. 2014;12:222. - PubMed
  24. Karagece Yalcin U, Seckin S. The expression of p53 and COX-2 in basal cell carcinoma, squamous cell carcinoma and actinic keratosis cases. Turk Patoloji Derg. 2012;28(2):119-127. - PubMed
  25. Van Haren R, Feldman D, Sinha AA. Systematic comparison of nonmelanoma skin cancer microarray datasets reveals lack of consensus genes. Br J Dermatol. 2009;161(6):1278-1287. - PubMed
  26. Spritz RA. The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma. Genome Med. 2010;2(10):78. - PubMed
  27. Calanchini-Postizzi E, Frenk E. Long-term actinic damage in sun-exposed vitiligo and normally pigmented skin. Dermatologica. 1987;174(6):266-271. - PubMed
  28. Bae JM, Chung KY, Yun SJ, et al. Markedly reduced risk of internal malignancies in patients with vitiligo: a nationwide population-based cohort study. J Clin Oncol. 2019;37(11):903-911. - PubMed
  29. Wen Y, Wu X, Peng H, et al. Cancer risks in patients with vitiligo: a Mendelian randomization study. J Cancer Res Clin Oncol. 2020;146(8):1933-1940. - PubMed
  30. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247-269. - PubMed
  31. Jackson B, Peyrollier K, Pedersen E, et al. RhoA is dispensable for skin development, but crucial for contraction and directed migration of keratinocytes. Mol Biol Cell. 2011;22(5):593-605. - PubMed
  32. Nikolova E, Mitev V, Minner F, et al. The inhibition of the expression of the small Rho GTPase Rac1 induces differentiation with no effect on cell proliferation in growing human adult keratinocytes. J Cell Biochem. 2008;103(3):857-864. - PubMed
  33. Winge MCG, Ohyama B, Dey CN, et al. RAC1 activation drives pathologic interactions between the epidermis and immune cells. J Clin Invest. 2016;126(7):2661-2677. - PubMed
  34. Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene. 1999;18(53):7644-7655. - PubMed
  35. Schallreuter KU, Behrens-Williams S, Khaliq TP, et al. Increased epidermal functioning wild-type p53 expression in vitiligo. Exp Dermatol. 2003;12(3):268-277. - PubMed
  36. Salem MM, Shalbaf M, Gibbons NC, Chavan B, Thornton JM, Schallreuter KU. Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage. FASEB J. 2009;23(11):3790-3807. - PubMed
  37. Liu X, Qing S, Che K, Li L, Liao X. Androgen receptor promotes oral squamous cell carcinoma cell migration by increasing EGFR phosphorylation. Onco Targets Ther. 2019;12:4245-4252. - PubMed
  38. Izikson L, Bhan A, Zembowicz A. Androgen receptor expression helps to differentiate basal cell carcinoma from benign trichoblastic tumors. Am J Dermatopathol. 2005;27(2):91-95. - PubMed
  39. Khachigian LM. The Yin and Yang of YY1 in tumor growth and suppression. Int J Cancer. 2018;143(3):460-465. - PubMed
  40. Wu S, Kasim V, Kano MR, et al. Transcription factor YY1 contributes to tumor growth by stabilizing hypoxia factor HIF-1alpha in a p53-independent manner. Cancer Res. 2013;73(6):1787-1799. - PubMed
  41. Chakravarti N, Mathur M, Bahadur S, et al. Retinoic acid receptor-alpha as a prognostic indicator in oral squamous cell carcinoma. Int J Cancer. 2003;103(4):544-549. - PubMed
  42. Ralhan R, Chakravarti N, Kaur J, et al. Clinical significance of altered expression of retinoid receptors in oral precancerous and cancerous lesions: relationship with cell cycle regulators. Int J Cancer. 2006;118(5):1077-1089. - PubMed
  43. Mishra A, Bharti AC, Saluja D, Das BC. Transactivation and expression patterns of Jun and Fos/AP-1 super-family proteins in human oral cancer. Int J Cancer. 2010;126(4):819-829. - PubMed
  44. Beck B, Lapouge G, Rorive S, et al. Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell. 2015;16(1):67-79. - PubMed
  45. Srivastava J, Rho O, Youssef RM, et al. Twist1 regulates keratinocyte proliferation and skin tumor promotion. Mol Carcinog. 2016;55(5):941-952. - PubMed
  46. Casamassimi A, Rienzo M, Di Zazzo E, et al. Multifaceted role of PRDM proteins in human cancer. Int J Mol Sci. 2020;21(7):2648. - PubMed
  47. Yan M, Yang S, Meng F, et al. MicroRNA 199a-5p induces apoptosis by targeting JunB. Sci Rep. 2018;8(1):6699. - PubMed
  48. Nairismägi M-L, Füchtbauer A, Labouriau R, et al. The proto-oncogene TWIST1 is regulated by microRNAs. PLoS One. 2013;8(5):e66070. - PubMed
  49. Zhao G, Li Q, Wang A, Jiao J. YY1 regulates melanoma tumorigenesis through a miR-9 ~ RYBP axis. J Exp Clin Cancer Res. 2015;34:66. - PubMed
  50. Li D, Li XI, Wang A, et al. MicroRNA-31 promotes skin wound healing by enhancing keratinocyte proliferation and migration. J Invest Dermatol. 2015;135(6):1676-1685. - PubMed
  51. Xu N, Meisgen F, Butler LM, et al. MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine/threonine kinase 40. J Immunol. 2013;190(2):678-688. - PubMed

Publication Types